

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](https://www.gov.uk/mhra)

## **Decision Cover Letter**

### **Decision of the licensing authority to:**

accept change(s) to the agreed paediatric investigation plan (MHRA-100283-PIP01-21-M01) and to the deferral

MHRA-100283-PIP01-21-M02

### **Scope of the Application**

#### **Active Substance(s)**

USTEKINUMAB

#### **Condition(s)**

Treatment of Crohn's disease

#### **Pharmaceutical Form(s)**

Concentrate for solution for infusion; Solution for injection

#### **Route(s) of Administration**

SUBCUTANEOUS USE; INTRAVENOUS USE

#### **Name / Corporate name of the PIP applicant**

Janssen-Cilag Limited

#### **Basis for the Decision**

Pursuant to the Human Medicines Regulations 2012, Janssen-Cilag Limited submitted to the licensing authority on 07/12/2022 06:46 GMT an application for a Modification

The procedure started on 01/03/2023 10:26 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](http://gov.uk/mhra)

## Final Decision Letter

MHRA-100283-PIP01-21-M02

Of 17/03/2023 08:30 GMT

On the adopted decision for USTEKINUMAB (MHRA-100283-PIP01-21-M02) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for USTEKINUMAB, Concentrate for solution for infusion; Solution for injection , SUBCUTANEOUS USE; INTRAVENOUS USE .

This decision is addressed to Janssen-Cilag Limited, 50-100 Holmers Farm Way, High Wycombe, UNITED KINGDOM, HP12 4EG

## ANNEX I

### 1. Waiver

#### 1.1 Condition:

Treatment of Crohn's disease The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 2 years of age Pharmaceutical form(s): Concentrate for solution for infusion; Solution for injection Route(s) of administration: SUBCUTANEOUS USE INTRAVENOUS USE Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

### 2. Paediatric Investigation Plan:

#### 2.1 Condition(s):

Treatment of Crohn's disease

## 2.2 Indication(s) targeted by the PIP:

Treatment of Crohn's disease

## 2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 2 years to less than 18 years of age

## 2.4 Pharmaceutical Form(s):

Concentrate for solution for infusion Solution for injection

## 2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Study 1 Deleted during procedure EMEA-000311-PIP04-13-M03.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	3	Study 2 (CNTO1275CRD1001) Randomised, double-blind, pharmacokinetic (PK) study of intravenous (IV) ustekinumab induction followed by subcutaneous (SC) ustekinumab maintenance in children and adolescents 2 to less than 18 years (6 to less than 18 years in the EU) with moderately to severely active Crohn's disease (CD) who have had an inadequate response and/or intolerance to conventional therapies. Study 3 (CNTO1257CRD3004) Open-label single administration of IV induction dose of ustekinumab followed by a randomised, double-blind, 2-arm study of two different SC ustekinumab maintenance dose regimens to assess the pharmacokinetics, safety and clinical response in children and adolescents 2 to less than 18 years with moderately to severely active Crohn's disease who have had an inadequate response and/or intolerance to biologic therapy and/or conventional therapies.

		Study 7 (added during procedure MHRA-100283-PIP01-21-M02) Retrospective, single-arm, non-interventional, observational, real world evidence study to evaluate the effectiveness of ustekinumab by estimating clinical remission at week 52 since initiation of ustekinumab in children and adolescents from 2 years to less than 18 years of age with moderately to severely active Crohn's disease.
<b>Extrapolation, Modeling &amp; Simulation Studies</b>	3	Study 4 (added during procedure EMEA-000311-PIP04-13-M01) Population PK model. Study 5 (added during procedure EMEA-000311-PIP04-13-M01) Exposure-response model. Study 6 (added during procedure EMEA-000311-PIP04-13-M01) Analysis of internal and literature data to support the assumptions of similarity of disease, treatment effects, and exposure-response relationship between paediatric and adult subjects with Crohn's disease (CD).
<b>Other Studies</b>	0	Not applicable.
<b>Other Measures</b>	0	Not applicable.

### 3. Follow-up, completion and deferral of a PIP:

<b>Concerns on potential long term safety and efficacy issues in relation to paediatric use:</b>	Yes
<b>Date of completion of the paediatric investigation plan:</b>	31/01/2027
<b>Deferral of one or more studies contained in the paediatric investigation plan:</b>	Yes

